Medline (NASDAQ:MDLN) Major Shareholder Sells $21,002,304.72 in Stock

Medline (NASDAQ:MDLN) major shareholder Private Ltd Gic sold 590,284 shares of the stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $35.58, for a total transaction of $21,002,304.72. Following the transaction, the insider owned 24,402,482 shares in the company, valued at approximately $868,240,309.56. The trade was a 2.36% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Private Ltd Gic also recently made the following trade(s):

• On Thursday, August 6th, Private Ltd Gic sold 271,994 shares of Medline stock. The stock was sold at an average price of $35.33, for a total transaction of $9,609,548.02.
• On Wednesday, August 5th, Private Ltd Gic sold 1,976,618 shares of Medline stock. The shares were sold at an average price of $35.60, for a total transaction of $70,367,600.80.

Medline Trading Up 0.2%

Shares of NASDAQ:MDLN opened at $35.58 on Friday. The company has a market capitalization of $46.74 billion and a P/E ratio of 111.19. Medline has a 1 year low of $32.81 and a 1 year high of $50.88. The company has a debt-to-equity ratio of 0.66, a current ratio of 4.33 and a quick ratio of 2.61. The business’s 50 day simple moving average is $38.26 and its 200 day simple moving average is $41.43.

Medline (NASDAQ:MDLN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of $0.32 by $0.18. The company had revenue of $7.68 billion for the quarter. On average, research analysts anticipate that Medline will post 1.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

MDLN has been the topic of several recent analyst reports. BTIG Research reissued a “buy” rating and issued a $55.00 target price on shares of Medline in a report on Friday, July 31st. Royal Bank Of Canada cut their price target on shares of Medline from $53.00 to $46.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Robert W. Baird set a $42.00 price objective on shares of Medline in a research note on Thursday, August 6th. Deutsche Bank Aktiengesellschaft set a $37.00 price objective on shares of Medline in a research report on Thursday, August 6th. Finally, Weiss Ratings upgraded Medline from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Medline currently has a consensus rating of “Moderate Buy” and an average target price of $47.42.

Medline News Summary

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline’s second-quarter results were a key support for the stock: earnings of $0.50 per share exceeded the $0.32 consensus estimate, while revenue reached approximately $7.7 billion. The earnings call provided investors with additional management commentary on the company’s outlook. Medline Q2 2026 earnings call transcript
• Positive Sentiment: JPMorgan lowered its price target to $46 but retained an Overweight rating, while TD Cowen and Tigress Financial maintained positive ratings with targets of $45 and $55, respectively. These targets imply meaningful upside and suggest some analysts view the recent weakness as excessive.
• Neutral Sentiment: Despite multiple target reductions, analyst sentiment remains broadly favorable. Medline has a consensus rating of “Moderate Buy,” although the average target has fallen to about $47.69, indicating that expectations are being recalibrated.
• Negative Sentiment: Medline convenience kits are affected by recalled Becton Dickinson applicators linked to sterility and contamination risks. The FDA alert and Medline’s corrective actions could create operational, regulatory and reputational concerns, although the report does not indicate the full financial impact. FDA alert on Medline convenience kits
• Negative Sentiment: Kaplan Fox and Kessler Topaz Meltzer & Check announced investigations into potential securities-law violations. The announcements do not establish wrongdoing, but they add legal uncertainty and may weigh on investor confidence. Kessler Topaz Medline investigation
• Negative Sentiment: Wells Fargo cut its price target to $34 and assigned an Equal Weight rating, signaling limited near-term upside. Major shareholder GIC also sold additional Medline shares, including 590,284 shares in the latest disclosed transaction, reducing its position by 2.36%.

Institutional Trading of Medline

A number of hedge funds and other institutional investors have recently modified their holdings of MDLN. Sound Income Strategies LLC bought a new position in shares of Medline in the 4th quarter valued at $25,000. GAMMA Investing LLC grew its position in Medline by 68.3% during the 2nd quarter. GAMMA Investing LLC now owns 626 shares of the company’s stock worth $25,000 after acquiring an additional 254 shares during the last quarter. Entrust Financial LLC acquired a new position in Medline in the 4th quarter worth about $26,000. NBC Securities Inc. bought a new position in Medline in the fourth quarter valued at about $28,000. Finally, Whipplewood Advisors LLC acquired a new stake in shares of Medline during the first quarter valued at about $30,000.

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.